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Abstract 
Background: Any treatment decision should be tailored to the individual patients` characteristics. A 
personalized approach aims to help better selecting the patients who are likely to benefit most from a 
treatment decision. In the SPRINT trial, intensive treatment reduced the rated of major cardiovascular 
events, but increased the rate of serious adverse events. 
Objectives: To assess the trade-off between efficacy and safety to simultaneously quantify an 
individual patient's absolute benefit and absolute harm, helping clinicians making better therapeutic 
choices in daily practice. 
Methods: Multivariable Cox Poisson regression models were used to identify independent risk factors 
for: 1) primary composite cardiovascular outcome=efficacy, and 2) major serious adverse events 
(SAEs)=safety. Estimates from the models were used to quantify each individual risk.  
Results: Sub-clinical cardiovascular disease, number anti-hypertensive agents, current smoking, age, 
urine albumin to creatinine ratio, and serum creatinine were associated with increased risk of both 
primary outcome events and SAEs. Triglycerides were associated with increased primary outcome 
events only, and chronic kidney disease and female sex with SAEs only. The models were well 
calibrated and showed good performance (c-index for safety=0.69 and c-index for efficacy=0.72). For 
the primary outcome, there is a steep gradient in risk by fifths of the predicted model and a similar 
gradient exists for the safety outcome predicted model. Mortality within 1-year of an efficacy 
outcome (as assessed by the Kaplan-Meier method) was nearly 3-fold higher than following a safety 
outcome (21.9% vs. 7.5%). If one judges the clinical importance of efficacy and safety outcomes 
based on their 1-year mortality, then there is a net benefit of intensive therapy for almost all patients.  
Conclusion: Anti-hypertensive treatment intensification is associated with lower cardiovascular event 
rates however it increases the risk of adverse events. The present analysis helps clinicians to perform 
individualized treatment decisions based on readily available risk models. 
 
Key-words: individualized anti-hypertensive treatment decisions; SPRINT trial; benefits; harms; 
intensive therapy. 
 
 
 
 
 
 
 
 
 
Introduction 
Individualized treatment decisions, also referred to as “personalized approach” is warranted to 
better select patients who will likely benefit most from a therapeutical decision. The potential benefits 
must be weighed against the potential harms, in a “trade-off” analysis that takes into account both the 
severity associated with an efficacy event and that associated with a safety adverse event. For 
example, if mortality is greatly increased after a non-fatal primary efficacy event, but not after an 
adverse event, then treating a patient will likely be beneficial even if an adverse event occurs along 
the way. In other words, a balanced account of both efficacy and safety must be provided1. 
Consideration of the number needed to treat for benefit versus the number needed to harm may 
provide a guide to net clinical benefit as long as the clinical severity of the events is taken into 
account2.  
In the SPRINT (A Randomized Trial of Intensive versus Standard Blood-Pressure Control) 
trial3, intensive anti-hypertensive treatment with the goal of lowering systolic blood pressure below 
120 mmHg resulted in a lower rate of the primary composite cardiovascular outcome (-1.6%) and a 
lower rate of death (-1.2%), compared to the rates observed with standard blood-pressure control 
(goal <140 mmHg). The benefits of intensive blood pressure lowering must be weighed against the 
increase in the serious adverse event rate. However, significantly higher rates of serious adverse 
events (SAEs) were observed in the intensive-treatment group, including reported serious adverse 
events or adverse events requiring emergency visit. For example, symptomatic hypotension (+1.4%), 
syncope (+1.1%), electrolyte abnormalities (+1%), and acute kidney injury or failure (+1.8%). 
Despite the small absolute difference in the benefits and risks, guideline committees, treating 
physicians, and patients may face a challenge when trying to determine which strategy to adopt. 
Hence, a “trade-off” analysis of potential benefits and harm may help in daily decision of whether 
intensify or not anti-hypertensive treatment in each individual patient. 
The main aims of the present analysis are: 1) to separately assess the absolute efficacy and the 
absolute safety of an intensive strategy vs. a standard strategy for individual patients whose risk 
profiles vary markedly; 2) to compute the theoretical net benefit associated with each patient profile; 
and 3) estimate the distributions of these net benefits on the whole SPRINT population. 
 
Methods 
Trial oversight 
SPRINT was sponsored by the NHLBI, with co-sponsorship by the National Institute of 
Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and 
Stroke, and the National Institute on Aging. The rationale and protocol for the trial have been 
previously published3 and are publicly available4. 
In short, participants were required to meet all the following criteria: an age of at least 50 
years, a systolic blood pressure of 130 to 180 mm Hg, and an increased risk of cardiovascular events 
(defined by one or more of the following: clinical or subclinical cardiovascular disease other than 
stroke; chronic kidney disease with an estimated glomerular filtration rate [eGFR] of 20 to 60 
ml/min/1.73m2; a 10-year risk of cardiovascular disease ≥15% on the basis of the Framingham risk 
score; or an age ≥75 years). Patients with diabetes mellitus or prior stroke were excluded. All 
participants provided written informed consent. Eligible participants were assigned to a systolic 
blood-pressure target of either less than 140 mm Hg (the standard-treatment group) or less than 120 
mm Hg (the intensive-treatment group). Participants and study personnel were aware of the study-
group assignments, but outcome adjudicators were not. The protocol encouraged, but did not mandate, 
the use of drug classes with the strongest evidence for reduction in cardiovascular outcomes5. 
Treatment adjustment was based on a mean of three blood-pressure measurements at an office visit 
while the patient was seated after 5 minutes of quiet rest; the measurements were made with the use of 
an automated measurement system (Model 907, Omron Healthcare). A structured interview was used 
in both groups every 3 months to obtain self-reported cardiovascular disease outcomes. Medical 
records and electrocardiograms were obtained for documentation of events. Whenever clinical site 
staff became aware of a death, a standard protocol was used to obtain information on the event. 
Serious adverse events were defined as events that were fatal or life-threatening, that resulted in 
clinically significant or persistent disability, that required or prolonged a hospitalization, or that were 
judged by the investigator to represent a clinically significant hazard or harm to the participant. A list 
of monitored conditions was also reported as adverse events if they were evaluated in an emergency 
department: hypotension, syncope, injurious falls, electrolyte abnormalities, and bradycardia. 
Occurrences of acute kidney injury or acute renal failure were also documented. The relationship of 
serious adverse events to the intervention was assessed by the trial safety officer and reviewed 
monthly by the safety committee. A total of 9361 participants were randomized in the SPRINT trial. 
The trial was stopped earlier than expected after analyses of the primary outcome exceeded the 
monitoring boundaries at two consecutive time-points. The median follow-up was 3.26 years. 
 
Study Outcomes 
The primary outcome of the SPRINT trial was a composite of myocardial infarction, other 
acute coronary syndromes, stroke, acute decompensated heart failure, or death from cardiovascular 
causes. In the present analysis, the primary outcome is referred to as the primary efficacy outcome. 
Compared with a standard systolic blood pressure target <140 mm Hg, the primary outcome was 
reduced by using an intensive systolic blood pressure target <120 mm Hg resulted in lower rates of 
fatal and nonfatal major cardiovascular events and death from any cause (6.8% vs 5.2% vs. 6.8%; 
hazard ratio [HR] =0.75; 95% confidence interval [CI[ =0.64-0.89; p<0.001). However Secondary 
outcomes included the individual components of the primary composite outcome, death from any 
cause, and the composite of the primary outcome or death from any cause. 
Compared with a systolic blood pressure target <140 mm Hg, an intensive systolic blood 
pressure target <120 mm Hg resulted in lower rates of fatal and nonfatal major cardiovascular events 
and death from any cause (5.2% vs. 6.8%; hazard ratio [HR] =0.75; 95% confidence interval [CI[ 
=0.64-0.89; p<0.001). However, the SPRINT trial also reported  significantly higher rates of SAEs 
were observed in the intensive-treatment group, including that several reported serious adverse events 
requiring emergency room visit,  as occurring more frequently in the intensive blood pressure 
monitoring. In particular, created a short-list of closely monitored serious adverse events consisting of 
the following conditions:  sor adverse events requiring emergency visit (symptomatic hypotension: 
(3.4% intensive vs. 2.0% standard, p<0.001); syncope: (3.5% vs. 2.4%, p=0.003); bradycardia: (2.2% 
vs. 1.8%, p=0.13); electrolyte abnormalities: (3.8% vs. 2.8%, p=0.006); and acute kidney injury or 
failure: (4.4% vs. 2.6%, p<0.001). In the present analysis we define the composite safety outcome as 
the time to occurrence of any of the above conditions.  
In the present analysis, the study primary outcome was set as the efficacy outcome, and the 
composite of SAEs was set as the safety outcome. 
 
Statistical analysis 
In descriptive analyses, continuous variables are expressed as mean ± standard deviation (SD) 
or median (percentile25-75interquartile range) based on their distribution assess by visual inspection. 
Categorical variables are expressed as frequencies and proportions (%). Population description and 
comparison of patients with “events” vs. “no events” was performed using independent samples t-test 
for normally distributed continuous variables, Mann-Whitney test for skewed variables, and chi-
square test for categorical variables. No multiple imputation was performed.  
 We graphically compared time to each of the primary efficacy and composite safety 
outcomes using Kaplan Meier curves. Since the rate of both outcomes was similar throughout the trial 
we additionally report annualized rates calculated from Poisson regression models. We compared the 
rate of mortality occurring after each outcome using the Kaplan Meier method, where the index time 
was defined as the date of occurrence of the event, and the time to mortality as the time between the 
event and death.  
To identify risk factors associated with each outcome, we used Using the total SPRINT trial 
population, multivariable Cox Poisson regression models were used to identify independent risk 
factors for: 1) primary outcome =efficacy and 2)  with forward stepwise variable selection, using 
p<0.05 as the criteria for inclusion. We considered the following patient characteristics for inclusion 
in the prognostic models: sex, age, race, smoking status, systolic and diastolic blood pressure, body 
mass index, total cholesterol, triglycerides, glucose, urine albumin to creatinine ratio, serum 
creatinine, statin and aspirin use, number of antihypertensive medications, prior cardiovascular 
disease history (clinical and/or subclinical) and presence of chronic kidney disease. We split 
continuous characteristics into tenths and compared risk across tenths in order to assess the correct 
functional form to enter into the model. There was only a small amount of missing data (6.4%), 
therefore we did not perform multiple imputation and we therefore performed covariate selection on 
the subset of patients with complete information on all candidate covariates (N=8,764) , and 
subsequently reported risk ratios using all patients with complete information on selected covariates 
(N=8,885)No multiple imputation was performed.. We assessed interactions with intensive blood 
pressure lowering for each of the primary efficacy outcome and composite safety outcome with 
baseline age, sex, baseline systolic and diastolic blood pressure, but none were significant (all 
p>0.05).  
 
The subtraction of the predicted risk with intensification from the predicted risk without 
intensification provided the absolute risk difference attributed to the intensification. The effect of 
intensification was assumed to be constant regardless of patient characteristics. , for efficacy and 
safety respectively.major SAEs composite =safety. Estimates from the models were used to assess 
individuals` risk by categorizing participants into five risk categories both for efficacy and safety. To 
simplify the risk score, integer points were assigned to each prognostic factor based upon the log-
hazard ratio estimates. The total risk score for each patient was calculated by summing the points 
across all chosen prognostic variables. The subtraction of the predicted risk with intensification from 
the predicted risk without intensification provided the absolute risk difference attributed to the 
intensification, for efficacy and safety respectively. Comparing for each individual the absolute 
predicted benefit to the absolute predicted harm allowed to determine whether benefit outweighs 
clearly harms, whether harms outweighs clearly benefit, or whether both are of the same magnitude.  
Within each risk category the number of events, person-years at risk, and the overall event rate were 
calculated. Kaplan–Meier plots were drawn to show the cumulative incidence curves by treatment 
group and risk category. The hazard ratio for “intensive-therapy” vs. “standard-therapy” was 
estimated in each risk group using a Cox proportional hazard model and the treatment by risk group 
interaction. Individual patient baseline data available and considered for inclusion in the prognostic 
model included sex, age, race, smoking status, systolic and diastolic blood pressure, body mass index, 
total cholesterol, triglycerides, glucose, urine albumin to creatinine ratio, serum creatinine, statin and 
aspirin use, number of antihypertensive medications, prior cardiovascular disease history (clinical 
and/or subclinical) and presence of chronic kidney disease. Linear effects and interactions (including 
treatment by predictor interactions) were investigated using likelihood ratio tests. Continuous 
variables were checked for linearity and worked to meet the proportional hazards assumptions. 
Categorization of continuous variables was performed using a combination of established clinical cut-
points, expert advice, and graphical examination of rates across quintiles.  
All analysis were performed with STATA® software (version 14). 
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 Results 
 
The SPRINT trial population consisted of 9361 patients with a mean age of 70 (SD=9), of 
whom 64.4% were male, with a mean baseline blood pressure of 139.7 (SD=15.6). Baseline 
characteristic were well balanced across treatment groups.  The primary efficacy outcome occurred in 
243 patients in the intensive-treatment arm and 319 patients in the control arm and 243 patients in the 
(risk ratio: 0.75, 95% CI 0.64 to 0.89), whereas the composite safety outcome occurred in 521 
intensive-treatment patients and 406 control patients XXX patients (risk ratio: 1.30, 95%CI 1.14 to 
1.48) (Figure 1 & Table 1). 
 
Amongst the 562927 patients who had a composite safety outcome 59 (7.5%) patients died 
within one year, whilst amongst the 562 patients with a primary efficacy outcome event 119 (21.9%) 
died within a year, representing a risk of death 2.92primary efficacy outcome, 119 (21.9%) died 
within , with no clear evidence of any difference in the mortality risk between the intensive and 
standard groups (XX.X% vs X.XX%, p=0.16) (Figure 2). The risk of death within a year of the 
composite safety outcome was 7.5% (59/927), again  
 
 times higher within the first year with a primary outcome rather than a composite safety 
outcome event (p<0.001, Figure 2). There was no clear evidence that risk of death following a 
primary efficacy outcome differed between the intensive  and standard group (23.8% vs 19.5%, 
p=0.16), nor was there any evidence that risk of death following a composite safety outcome differed 
between treatment groups (8.2% vs. 6.9%%, p=0.28 respectively).  
 
Table 2 shows the covariates selected for each of the Ttwo risk models were created : one for 
efficacy and another for safety. Sub-clinical cardiovascular disease, number anti-hypertensive agents, 
current smoking, age, urine albumin to creatinine ratio, and serum creatinine were associated with 
increased risk of both primary outcome events and SAEs. Triglycerides were associated with 
increased primary outcome events only, and chronic kidney disease and female sex with SAEs only. 
The models were well calibrated and showed good performance discrimination (c-index for 
safety=0.69 and c-index for efficacy=0.72); .  fFor theboth outcomes  primary outcome, there is a 
steep gradient in risk by fifths of the predicted modelrisk (Figure 3). A similar gradient exists for the 
safety outcome predicted model. 
 
However, because the covariates included in each risk model were similar, Tthe predicted risk 
of a primary efficacy outcome and composite safety outcome were models showed highly correlation 
correlated (Pearson=0.80; Figure 4)79), meaning that patients at high risk of the efficacy outcome also 
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tended to be at high risk of the safety outcome. .As a consequence,  For the primary outcome, there is 
a steep gradient in risk by fifths of the predicted model. A similar gradient exists for the safety 
outcome predicted model. Tthe trade-off of in predicted absolute efficacy benefit versus versus 
predicted absolute safety harm tended to be similar for most patients (Figure 5). for an intensive 
treatment strategy in all the 9361 individuals is shown in the Figure 1. If the efficacy and safety 
outcomes were considered clinically similar, then the few patients would have a net benefit from 
intensive treatment majority of patients (10.9%, 972/8885)would have a net loss by intensive 
treatment, since  (the composite safety outcomes occurred more frequently) than the primary efficacy 
outcome. However, mortality within 1-year of an efficacy outcome was nearly 3-fold higher than 
following a safety outcome (21.9% vs. 7.5%). Iif one judges the clinical importance of efficacy and 
safety outcomes based on their 1-year mortality, then there is a net benefit of intensive therapy for 
almost all patients (98.4%, 8743/8885). 
 
 
Discussion 
 
Conclusion 
Anti-hypertensive treatment intensification is associated with lower cardiovascular event rates 
however it increases the risk of adverse events. The present analysis helps clinicians to perform 
individualized treatment decisions based on readily available risk models. For any hypertensive 
patient (without diabetes or prior stroke) knowing his predicted absolute 3-year annual cardiovascular 
benefit and his predicted absolute annual  3-year harm for adverse events will aid clinical judgement 
as to whether therapy intensification is warranted. 
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Table 1:Baseline characteristics by treatment group
Table 12: Frequency of primary outcome, composite safety outcome and their components by treatment group 
Outcome Standard  Intensive % difference in annual 
event rate (95% CI) 
Relative risk (95% 
CI) 
P-value 
 N 
event 
Annual 
event 
rate (%) 
 N 
event 
Annual 
event 
rate (%) 
   
Primary outcome 243 1.7%  319 2.2% -0.5 (-0.9 to -0.2) 0.75 (0.64 to 0.89) 0.0009 
Myocardial infarction 97 0.7%  116 0.8% -0.1 (-0.3 to 0.1) 0.83 (0.63 to 1.09) 0.1795 
Acute coronary 
syndrome 
40 0.3%  40 0.3% -0.0 (-0.1 to 0.1) 1.00 (0.64 to 1.55) 0.9888 
Stroke 60 0.4%  69 0.5% -0.1 (-0.2 to 0.1) 0.87 (0.61 to 1.22) 0.4127 
Heart Failure 61 0.4%  98 0.7% -0.3 (-0.4 to -0.1) 0.62 (0.45 to 0.85) 0.0032 
Cardiovascular death 35 0.2%  58 0.4% -0.2 (-0.3 to -0.0) 0.60 (0.40 to 0.92) 0.0176 
         
Composite safety 
outcome 
521 3.8%  406 2.9% 0.9 (0.4 to 1.3) 1.30 (1.14 to 1.48) 0.0001 
Hypotension 110 0.8%  66 0.5% 0.3 (0.1 to 0.5) 1.67 (1.23 to 2.26) 0.0010 
Syncope 107 0.7%  80 0.6% 0.2 (0.0 to 0.4) 1.34 (1.00 to 1.79) 0.0497 
Bradycardia 87 0.6%  73 0.5% 0.1 (-0.1 to 0.3) 1.19 (0.87 to 1.62) 0.2761 
Electrolyte abnormality 144 1.0%  107 0.7% 0.3 (0.0 to 0.5) 1.35 (1.05 to 1.73) 0.0196 
Injurious fall 105 0.7%  110 0.8% -0.0 (-0.2 to 0.2) 0.95 (0.73 to 1.24) 0.7129 
AKI or acute renal failure 193 1.3%  117 0.8% 0.5 (0.3 to 0.8) 1.66 (1.32 to 2.08) 0.0000 
Table 23: Risk ratios for covariates selected for the risk prediction models 
 
Characteristic Primary outcome 
 
Composite safety outcome 
 Risk ratio (95% CI) P-value 
 
Risk ratio (95% CI) P-value 
Intensive therapy 0.74 (0.62 to 0.88) 0.0005 
 
1.29 (1.13 to 1.47) 0.0002 
Age (per 5 years higher)  1.24 (1.18 to 1.31) <0.0001 
 
1.25 (1.20 to 1.30) <0.0001 
Log albumin creatinine ratio (per 
doubling) 
1.19 (1.14 to 1.24) <0.0001 
 
1.15 (1.11 to 1.19) <0.0001 
Sub-clinical CVD 2.16 (1.81 to 2.59) <0.0001 
 
1.42 (1.21 to 1.66) <0.0001 
Number of anti-hypertensive agents 1.12 (1.03 to 1.21) 0.0099 
 
1.14 (1.07 to 1.22) 0.0001 
Current smoker  1.81 (1.41 to 2.31) <0.0001 
 
1.59 (1.30 to 1.95) <0.0001 
Log serum creatinine (per doubling) 1.29 (1.05 to 1.57) 0.0130 
 
1.28 (1.01 to 1.64) 0.0414 
Log triglycerides (per doubling) 1.25 (1.11 to 1.41) 0.0002 
   Sub-clinical CKD   
 
1.30 (1.05 to 1.60) 0.0141 
Female sex   
 
1.17 (1.00 to 1.36) 0.0550 
 
Figure 1: Kaplan Meier curves for time to event for primary outcome and composite safety outcome 
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Figure 2: Kaplan Meier plots of time to death following a) primary outcome, b) safety outcome  
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Figure 35: Predicted and observed risk by 6 categories of predicted risk  
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 Figure 34: Predicted annual event rate for primary outcome and composite safety outcome 
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Figure 45. Individual patient trade-off between the predicted 3-yearannual increase in primary 
efficacy outcome risk, and the predicted decrease in composite safety outcome  risk when using 
intensive therapy vs standard therapy.  
 
 
Figure 5: Predicted and observed risk by 6 categories of predicted risk  
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